<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047446</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0424</org_study_id>
    <nct_id>NCT04047446</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine vs Dexamethasone ISB</brief_title>
  <official_title>Prolonging the Interscalene Brachial Plexus Block by Adding Liposomal Bupivacaine or Preservative Free Dexamethasone to Bupivacaine: a Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients receiving shoulder arthroscopy will receive an interscalene block for
      pain management containing either liposomal bupivacaine and standard bupivacaine or standard
      bupivacaine and dexamethasone. Patients will be followed up with to determine postoperative
      pain and block duration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Anticipated">December 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical rating scale (NRS) pain at rest over 72 hours</measure>
    <time_frame>First 72 hours pain</time_frame>
    <description>NRS pain at rest averaged over the first 72 hours. NRS pain is on a scale from 0 (no pain at all) to 10 (worst pain imaginable). Patient reported pain at 24, 48, and 72 hours are averaged to produce this number.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical rating scale (NRS) pain at rest</measure>
    <time_frame>Postanesthesia care unit (0-6 hours postoperative), postoperative day 1, postoperative day 2, postoperative day 3, postoperative day 4, postoperative day 7</time_frame>
    <description>NRS pain is on a scale from 0 (no pain at all) to 10 (worst pain imaginable) and is patient reported for pain at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical rating scale (NRS) pain with movement</measure>
    <time_frame>Postanesthesia care unit (0-6 hours postoperative), postoperative day 1, postoperative day 2, postoperative day 3, postoperative day 4, postoperative day 7</time_frame>
    <description>NRS pain is on a scale from 0 (no pain at all) to 10 (worst pain imaginable) and is patient reported for pain with movement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>Postanesthesia care unit (0-6 hours postoperative), postoperative day postoperative day 1, postoperative day 2, postoperative day 3, postoperative day 4, postoperative day 7</time_frame>
    <description>Opioid consumption, measured in oral morphine equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with pain management: scale</measure>
    <time_frame>Postanesthesia care unit (0-6 hours postoperative), postoperative day 1, postoperative day 2, postoperative day 3, postoperative day 4, postoperative day 7</time_frame>
    <description>Patient reported satisfaction on a scale of 0 (not satisfied) to 10 (complete satisfaction). This is patient opinionated and is reflective with patient contentedness with their pain management. Higher scores indicate greater satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory short-form</measure>
    <time_frame>Postanesthesia care unit (0-6 hours postoperative), postoperative day 1, postoperative day 2, postoperative day 3, postoperative day 4, postoperative day 7</time_frame>
    <description>The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. It consists of 4 severity items, which, when averaged, can be used as a measure of pain severity. Higher scores indicate more pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of analgesic block</measure>
    <time_frame>24, 48, 72, 96 (if needed) hours postoperatively</time_frame>
    <description>Patients are contacted and asked questions regarding their motor strength and sensation in their shoulder. Patients are asked &quot;When did your pain relief from the block completely wear off?&quot; This indicates the block duration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Shoulder Pain</condition>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine &amp; standard bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard bupivacaine &amp; dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel 133 MG Per 10 ML Injection</intervention_name>
    <description>10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)</description>
    <arm_group_label>Liposomal bupivacaine &amp; standard bupivacaine</arm_group_label>
    <other_name>Liposomal Bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>15mL of 0.5% bupivacaine with 4mg of preservative-free dexamethasone will be injected</description>
    <arm_group_label>Standard bupivacaine &amp; dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-III

          -  Age 18 years or older

          -  Scheduled for elective outpatient arthroscopic shoulder surgery

        Exclusion Criteria:

          -  History of allergy to local anesthetic, or one of the study medications

          -  Pre-existing neurological deficits

          -  Psychiatric or cognitive disorders that prohibit patients from following study
             protocol

          -  History of drug or alcohol abuse

          -  Chronic opioid use (longer than 3 months)

          -  Chronic pain syndromes

          -  Infection at the site of injection

          -  Patients with severe pulmonary disease

          -  Herniated cervical disc, cervical myelopathy

          -  Contraindication for general anesthesia and/or interscalene nerve block

          -  Pregnancy

          -  Open shoulder arthrotomies.

          -  Non English speakers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George Birch, BS</last_name>
    <phone>(212) 774-7377</phone>
    <email>birchg@hss.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Audrey Tseng, BS</last_name>
    <phone>(646) 797-8535</phone>
    <email>tsenga@hss.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Birch, BS</last_name>
      <phone>212-774-7377</phone>
      <email>birchg@hss.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

